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In this article, we examine and
discuss the current situation for
noncommercial clinical trials in
Europe—two years after a new legal
framework entered into force. The
Clinical Trials Directive, issued in
2001 [1], sought to regulate clinical
research in a uniform way across
Europe. The basic aims underpinning
its development were to cut red tape,
speed up research and development,
enhance the quality of investigational
drugs, harmonise procedures, increase
thetransparencyoftheclinicalresearch
process, and last, but not least, enforce
patient protection. The Directive
required that trialists and sponsors
ensure ethical review and authorisation
by competent national authorities
before enrolling participants, drug
manufacture in line with Good
Manufacturing Practice guidelines, and
rigorous observance of the Good
Clinical Practice (GCP) principles
during the conduct of the trial.
Furthermore, the Directive required
that any changes related to the
execution of the clinical study, and its
ﬁnal results, be reported to the
supervising authorities. To transpose
the Directive into national law, each
European Union (EU) member state has
had to change its established legal
framework for clinical drug research to
meet the requirements of the Directive.
S i n c et h a tt i m e ,t h eD i r e c t i v eh a s
fundamentally changed the face of
clinical research in Europe. While the
pharmaceutical industry has become
accustomed to intervening early in
political decisionmaking and legislative
processes, public and academic research
institutions have taken more time to
d e v e l o pac o m m o na c t i o np l a ni n
response to the Directive [2,3]. Perhaps
due to the legal complexity of the
subject, responses to the Directive’s
impact on noncommercial research
have been limited to surveys [4,5].
Attempts to convey the current
situation in the EU are restricted by
language and information barriers and
by insufﬁcient resources for conducting
a Europe-wide analysis.
Harmonisation Still Outstanding
When trying to understand how the EU
Clinical Trials Directive (CTD 2001/20)
has been applied across Europe, our ﬁrst
question is whether the original goal of
harmonisation has been achieved. A
comparison of revised legislative texts in
eight EU member states shows that
differences remain for many types of
clinical trials (Figure 1). France appears
to have the most comprehensive legal
deﬁnition on biomedical research, with
public authorities rigorously supervising
all kind of trials, including those on
cosmetics. The Directive was set up with
the intention of governing clinical
research into medicinal products
(medicines, drugs). Therefore, problems
may arise in applying the Directive to
trials that investigate complex modes of
treatment (e.g., surgical techniques, or
combinations of drugs and devices). As
shown in Figure 1, many borderline
situations will occur in future trials,
making it difﬁcult to determine whether
a trial falls under the new regulation
or not. Such problems are even more
far-reaching if a multicentre trial in-
vestigating complex modes of treatment
is carried out in many different European
countries.
There is the same lack of harmonisation
in relation to the way the Directive
applies to noncommercial trials across
the EU. The Directive itself contains only
two areas where exceptions are allowed
for noncommercial trials, but these only
apply where the drug is already marketed
and used in line with its marketing
authorisation: 1) labelling requirements
for the investigational drug are less
stringent; 2) dossier submission to
national authorities can be relaxed in
certain ways.
These two exceptions have been
adopted in similar ways throughout
Europe, but they apply only to a small
subset of trials, known as therapeutic use
studies.
The term noncommercial trial emerged
from the Clinical Trial Directive. But only
two of the eight member states compared
in Figure 1 (Italy and Belgium) have put
in place legislation that recognises the
potential beneﬁts of noncommercial
clinical trials to patients and public
health. Other member states claim that
such exceptions are difﬁcult to reconcile
with the universally protective character
of the legislation on medical research in
humans, in view of the repeated mentions
of universal patient protection in the
GCP-Directive 2005/28/EC [6], issued as
an addendum to the CTD 2001/20. In
addition, no common deﬁnition exists in
the EU to explain what a noncommercial
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ranging, including experimental research
into new, unapproved chemical or
biological entities, and therapeutic use
research into established, approved
drugs. For example, therapeutic use
research examines the effects of varying
dosage or application schedules, with the
intention of improving day-to-day
medical practice.
Major Obstacles and Unsolved
Issues
Since the Directive’s application, key
problems have been reported by
academic researchers in published
letters and conference presentations
[2,3]: 1) a requirement for single
sponsorship for multicentre and, more
demandingly, pan-European multicentre
studies; 2) deﬁnition of the investigational
medicinal product (IMP). The key
question here is what portion of a
patient’s comprehensive medication
scheme constitutes background and/or
supportive medication and what portion
is exerting the pharmacological effect
under investigation; 3) free-of-charge
supply principle of the investigated
medicine, which requires that trial
sponsors provide the IMP for free; 4)
increased cost of insurance coverage; 5)
increased cost of quality assurance
systems for supervision of ongoing trials;
and 6) increased cost of submissions to
ethics committees, national authorities,
and fees for GCP inspections, carried out
by national authorities or the European
Medicines Agency (EMEA).
T h e s ea r eap a r t i c u l a rb u r d e nf o r
noncommercial trials, and for
investigators who want to start their
own, independent research.
A comparative analysis of member
states’ provisions illustrates that the
promises of the Directive have not been
fulﬁlled (Table 1). To resolve liability
issues, in each country cascades of
agreements have been required between
investigators and hospitals, hospitals and
their public or private shareholders, and
between hospitals’ owners and the state
authorities. It appears that member states
with tax-ﬁnanced public health systems,
such as in the UK or Sweden, have found
it easier to solve the liability problem of
public sponsors. For example, in the UK,
the Medicines and Healthcare Products
Regulatory Agency (MHRA), Universities
UK, and the Department of Health have
carried out a regulatory impact
assessment [7]. This assessment has
enabled charities and associations in the
UK to act as a sponsor in multinational
studies taking place across the EU.
The European Commission has
recently provided a new deﬁnition for
non-IMPs (NIMP), clarifying the current
situation considerably [8]. The new
deﬁnition states that ‘‘support or escape
medication for preventive, diagnostic or
therapeutic reasons’’ or medications
‘‘used in accordance with the protocol
to induce a physiological response’’
should be distinguished from an IMP.
However, many other aspects of the
Directive still remain to be commonly
understood or adopted (Table 1). For
example, the issue of reimbursement of
commercially available drug supplies by
public health insurance systems is still
problematic. For trials in HIV or
oncology that test the best therapeutic
use of innovative medicines in
combination with existing therapy
schemes, the free-of-charge supply
implicates a cost takeover of
investigated medicines as well as of
established co-medications. In Italy,
Belgium, Sweden, and the Netherlands,
speciﬁc mechanisms have been set up for
noncommercial trials, which allow for
public cost takeover for tested drugs
and co-medications (support or
background treatments). Although the
processes differ between countries, these
provisions nevertheless show the
willingness of some national
policymakers to encourage patient-
oriented research and access to new
therapies. In the ﬁelds of pediatrics and
research into rare diseases, clinical trials
provide a key role in giving patients
access to innovative treatments.
DOI: 10.1371/journal.pctr.0010013.g001
Figure 1. Schematic Presentation of Differences in the Scope of National Laws Governing Clinical Trials in Europe
Legislative acts in each member state were recently revised to cope with the requirements of the CTD 2001/20/EC. Shadowed boxes indicate revised
legislation in response to the Directive. The German ordinance on irradiation protection (Strahlenschutzverordnung) and the Italian decree on clinical
research for the improvement of clinical practice (Decreto 17 Dec 04) constitute two accompanying legal acts. The term multi-modal therapy trials refers
to trials that evaluate the effects of drug therapy together with other forms of medical intervention, e.g., irradiation, surgery, other procedures.
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problems caused by the CTD 2001/20
arise from the multitude of liabilities
effected by each clinical trial. Many of
the open questions have to be solved by
each individual EU member state. Each
state is responsible for tort and liability
issues, for public health care provisions
including reimbursement, and for science
and research [9]. Therefore, rules for
noncommercial trials in the EU continue
to be divergent: on the one hand, clinical
trials are subject to the harmonisation
obligations of the EU, and, on the other
hand, they are subject to the legal codes of
each individual member state where the
trial is conducted. This discrepancy
inevitably leads to a signiﬁcant rise in
administrative workload for large,
multinational clinical trials because such
trials must obey a host of different
administrative requirements in each
country in which they are conducted.
Today, sponsors of multinational trials
have to cope with the need to obey
complex and differing codes of law
across all the countries they are working
in. In most EU member states, the laws
have several enclosures in the form of
lengthy guidance documents with dozens
of chapters and up to 100 text pages.
Beneficial Effects
Patient protection was highlighted as one
of the main reasons behind the Directive.
One controversial issue that remains
relates to the protection of incapable,
critically ill patients [10,11]. The Directive
requires that surrogate consent from a
nominated legal representative is
provided before critically ill patients
without relatives can be enrolled in a
clinical trial. This requirement has been
tackled in different ways by each member
state, and has an obvious impact on
emergency care research.
Historically, investigational medicines
used in trials could be produced in
facilities without extensive Good
Manufacturing Practice. Now, the
Directive lays out strict regulations
governing manufacture of investigational
drugs (technical rules and guidelines set
out in Volume 4 of the EudraLex
catalogue [12]). The Directive therefore
minimises risks for trial participants that
might arise from defective or poor quality
investigational drugs.
The Directive’s request to provide a
ﬁnancing or fundraising plan enhances
transparency. The obligatory registration
of clinical trials and the intended
publication of key information on
ongoing trials in public databases (such
as the planned public module of the
EudraCT database) constitute a major
beneﬁcial achievement. Increased
transparency is also a key part of the
revised EU pharmaceutical legislation,
which has been in place since November
2005 [9]. This legislation aims to provide
the public with better information on
clinical trials, medicines, and public
health issues.
The Directive might also be seen as a
route towards reducing the number of
unoriginal or poorly conducted clinical
trials (i.e., protocols not followed
properly), or those that are poorly
managed (i.e., trial supervision is
inadequate or data management
procedures not well done or biased).
The Directive may lead to better quality
of research in both commercial and
noncommercial ﬁelds with the hope that
in the future the number of ‘‘me-too’’
trials and products might decline. In this
context, the limited funding for clinical
research in the EU will play a major role.
Governmental and nongovernmental
funding bodies will need high-calibre
expertise if they want to base future
funding decisions on project excellence.
Prospects
More than ever before, funding will be a
key issue for noncommercial clinical
research. Remarkable work in this
respect has been done recently by the
European Cancer Research Managers
Forum, which has recently examined
Europe-wide funding in cancer research
[13]. Based on ﬁgures obtained before the
EU was enlarged, the level of funding for
noncommercial clinical research in the
US is ﬁve times higher per capita than in
Europe. Europe’s capacity to preserve its
expertise and leading position in clinical
research therefore crucially depends on
the available public and private funding.
Table 1. Country-Specific Provisions for Noncommercial Clinical Trials in Different EU Member States
Relevant Issue Country
Belgium France Germany Italy Netherlands Spain Sweden UK
Definition of a non-interventional trial PP
a PP O
b PP P
Concept of noncommercial trials PP
c OP O O O O
Provisions for cost takeover for IMP PO
a TBD
d P
e PO P
e P
f
Waiver for ethics committees fees PO P
g PP
g OO O
Waiver for competent authorities fees PP O P
h NA OP O
Risk-assessment approach for monitoring extent
j TBD PP P O O TBD P
IMP labelling alleviations
i All member states in line with provisions given by Article 14 CTD 2001/20 and Article 32 EU GMP Guide
IMPD submission facilitations
i All member states in line with provisions given by Table 1 in guidance document on CTA revision 2 [8]
EU member states with a relevant position in clinical research were chosen for analysis in terms of their capacity to fund cancer research (nonclinical, translational, and clinical) [13],
taking into account both public and private charity funding and population.
aLegislative transposition was completed in April 2006 by publication of Decree 2006-477.
bThe Dutch classification system uses the term observational studies as determined by the (good) pharmaceutical practice code (CSG).
cFrench legislation uses the term institutional trials in statutory documents.
dThe recent amendment of the German Drug law (14th, A ¨nderung des Arzneimittelgesetzes, (known as 14th AMG-Novelle from September 2005) reintroduces provisions into German
law that public health care insurers participate proportionally into trial-related costs. At the moment it is unclear to what extent IMPs are reimbursed if used within, similarly to, or
outside an existing marketing authorization.
eItaly: waiver approval/assignment by an ethics committee; Sweden: waiver decision by the Swedish competent authority, the MPA.
fCost takeover is allowed where an IMP is authorized in the UK and considered standard therapy by the National Health Service.
gDecision is at each ethics committee’s discretion. In the case of the Netherlands, fees are only payable to local ethics committees.
hA waiver for inspection fees is also planned.
iFor trials investigating an approved medicinal product in accordance with its marketing authorisation.
jCurrently in discussion/preparation.
P, Yes; O, No; GMP, good manufacturing practice; IMPD, IMP dossier; NA, not applicable; TBD, to be determined.
DOI: 10.1371/journal.pctr.0010013.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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academic institutions are to maintain
their role in supporting research that
will improve patient care.
At present, it’s not clear how the
problems reported in this article can be
resolved. A new Directive (GCP-Directive
2005/28/EC [6]), was due to be
implemented through the EU by the
end of January 2006. This new Directive
gives member states more ﬂexibility to
legislate on noncommercial trials, stating
that ‘‘the conditions under which the
noncommercial research is conducted by
public researchers and the places where
this research takes place, make the
application of certain of the details of
good clinical practice unnecessary or
guaranteed by other means.’’ But will
countries who have just made changes to
legislation, and who voted for a rather
restrictive handling of noncommercial
clinical research, reopen the gates for
more and easier research? Any answer is
speculative, particularly given that the
EU Commission’s eagerly awaited,
additional guidance on noncommercial
trials has not yet been released.
The European approach to regulation
of clinical trials is an administrative and
procedural one. A drug’s sponsorship
and development stages only play
subordinated roles. For drugs with an
existing marketing authorisation, the
Summary of Product Characteristics
serves as a landmark for all future trials.
As regulations become more and more
burdensome, many therapeutic
interventions are excluded from routine
practice, restricted to off-label
application, or used in clinical trials only.
In the past, clinical trials carried out
with paediatric patients or with those
with rare diseases often legitimized the
use of innovative medicines. Results from
such trials were often necessary to
convince health insurers to take over the
costs of therapy for drugs not yet
accepted for ofﬁcial reimbursement.
Recent forecasts and ﬁrst survey results
gave evidence for a 30%–50% drop in the
number of new noncommercial clinical
trials started in the EU since 2004 [14].
This leads to fewer opportunities to gain
access to innovative drugs. In paediatric
oncology, there are fears that the decline
of clinical research will result in poorer
outcomes for patients.
How can the situation be improved? In
the EU, any systematic change in a drug’s
application from the approved use
described on its label means that any
clinical investigation must conform to all
requirements of the CTD 2001/20. In
many member states, policies for
graduated application review or risk
assessment strategies for clinical trials
do not exist, although these are urgently
needed. A comparison with the US is
illuminating (Figure 2) [15,16]. In the US,
a single initial investigational new drug
(IND) dossier has to be established for a
nonmarketed drug before clinical tests
can start. All subsequent trial protocols
are submitted as amendments to the IND.
In contrast, the EU Directive requires a
stand-alone dossier submission for each
trial protocol, and in each member state.
The US Food and Drug Administration
(FDA) allows exemptions from IND
submission for non-interventional trials
and trials for patients with life-
threatening diseases or a lack of good
therapeutic alternatives. This offers
clinicians more choice in patient-
focused research. Establishing such a
risk-assessment approach along with a
single European trial evaluation and
approval process for multinational
clinical studies should be top priorities
for policymakers in order to keep the
European clinical trials’ environment
competitive [17]. “
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